<DOC>
	<DOCNO>NCT02830932</DOCNO>
	<brief_summary>A Phase 1 , Randomized , Double-Blind , Placebo-Controlled , Dose-Ranging Trial Determine Safety Immunogenicity Adenoviral-Vector Based Respiratory Syncytial Virus ( RSV ) F Protein Vaccine ( VXA-RSV-f ) Expressing Protein F dsRNA Adjuvant Administered Orally Healthy Volunteers</brief_summary>
	<brief_title>Dose-Ranging Trial Safety &amp; Immunogenicity Oral Adenoviral-Vector Based RSV Vaccine ( VXA-RSV-f )</brief_title>
	<detailed_description>The study enroll 66 subject four cohort . All subject receive single administration VXA-RSV-f low dose , high dose placebo . Two sentinel group enroll 3 subject open-label manner ( Cohorts 1 3 ) receive VXA-RSV-f prior enrol either randomize , control cohort ( Cohorts 2 4 ) . Within double-blinded Cohorts ( 2 4 ) , placebo subject receive number tablet vaccine subject Cohort . Subjects enrol dosed low dose group prior initiation dose high dose group . Cohort 1 : 3 subject low dose Cohort 2 : 20 subject low dose 10 placebo Cohort 3 : 3 subject high dose Cohort 4 : 20 subject low dose 10 placebo Subjects follow 28 day post vaccination preliminary immunogenicity . Subjects continue follow 1 year post-vaccination long term safety .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female volunteer age 18 49 year , inclusive 2 . Able give write informed consent 3 . Healthy ( clinically significant health concern ) 4 . Safety laboratory value within follow range criterion normal range 5 . Body mass index 17 35 screen 1 . Receipt investigational RSV vaccine within two year prior study 2 . Receipt investigational vaccine , drug device within 8 week precede vaccination 3 . Administration license vaccine within 30 day prior study 4 . Presence significant uncontrolled medical psychiatric illness ( acute chronic ) include institution new medical/surgical treatment significant dose alteration uncontrolled symptom drug toxicity within 3 month screen reconfirm baseline 5 . History drug , alcohol chemical abuse within 1 year prior vaccination 6 . Presence fever â‰¥ 38oC measure orally baseline 7 . Stool sample occult blood screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>